Amorfix achieves technical milestone in development of a blood test for Alzheimer's disease
Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced the achievement of the technical milestone of demonstrating that Amorfix's Epitope Protection (EP) technology is able to detect protected sites within Abeta amyloid aggregates which are formed in Alzheimer's disease. With this advancement, Amorfix will be committing additional resources to develop an ultra-sensitive blood test for Alzheimer's disease, EP-AD(TM), based upon Amorfix's patent-pending EP technology.
Pursuant to the subscription agreement executed January 30, 2006, OGI will now invest its second tranche of $50,000 in Amorfix. This transaction is subject to acceptance for filing by the TSX Venture Exchange.
Most read news
Organizations
Other news from the department research and development
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.